Guggenheim has initiated its coverage of psychedelic drug developer Cybin (NYSE:CYBN) with a Buy rating and a $35 per share ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday. MDD ...

The Daily Gate mobile app brings you the latest local breaking news, updates, and more. Read the Daily Gate on your mobile device just as it appears in print.

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

The FDA in 2019 approved Spravato, a close chemical relation to ketamine, in combination with an oral antidepressant for adults with treatment-resistant depression. Spravato generated sales of $ ...

has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value threshold. The spray – which was approved by the FDA in ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion, stellate ...